BioSpace News Archive

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced it has retained Perella Weinberg Partners (PWP) as a financial advisor to assist the Company in exploring strategic alternatives.

Veloxis Pharmaceuticals Inc., an Asahi Kasei company, today announced that VEL-101, a novel investigational maintenance immunosuppressive agent being developed for prophylaxis of renal allograft rejection in patients receiving a kidney transplant, was granted fast track designation by the U.S. Food & Drug Administration (FDA).

Proceeds to accelerate the commercial deployment of Neo Medical AI-driven ADVISE™ augmented reality platform for spinal surgery.

LEO Pharma A/S today announced it has appointed Brian Hilberdink new Executive Vice President and President of LEO Pharma Inc. in the United States, effective March 14, 2022.

Edesa Biotech, Inc. today provided an update on the Phase 3 part of a Phase 2/3 clinical study evaluating the company’s monoclonal antibody candidate, designated EB05, as a single-dose therapy for hospitalized Covid-19 patients.

Establishment Labs Holdings Inc. announced that it has surpassed two million Motiva Implants ® in market.

Paragon 28, Inc. announced it will report financial results for the fourth quarter and full year 2021 after market close on Tuesday, March 8, 2022.

Natera, Inc. announced the results of a large, real-world study confirming strong performance of its Prospera donor-derived cell-free DNA (dd-cfDNA) test in assessing rejection for kidney transplant patients.

Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that on February 16, 2022, the Company entered into a strategic cooperation framework agreement (the “Agreement”) with Beijing Jinshengyun Pharmaceutical Technology Co., Ltd. (“JSY”).

Movano Inc. (NASDAQ:MOVE), today announced the completion of an Institutional Review Board (IRB)-approved glucose pilot study, which was conducted on 10 participants with type 1 diabetes of varying gender, age, ethnicity and weight in conjunction with an independent FDA-compliant clinical lab.